Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027 LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. “We are pleased to publish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results